Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox)

Ruth L. Quispe; Michael L. Jaramillo; Frank Torres-Huaco; Cesar Bonilla; Jacqueline Isasi; Clara Guerra-Duarte; Carlos Chávez-Olórtegui

doi:10.1016/j.toxicon.2022.05.044

Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox)

Ruth L. Quispe, Michael L. Jaramillo, Frank Torres-Huaco, Cesar Bonilla, Jacqueline Isasi, Clara Guerra-Duarte, Carlos Chávez-Olórtegui

Research output: Contribution to journal › Original Article › peer-review

Abstract

Loxoscelism is a serious public health problem in Peru, with approximately 2500 accidents reported per year. To envision alternatives to cope with this health problem, the neutralizing humoral immune response against the lethal effects of Peruvian spider Loxosceles laeta venom was evaluated in a mouse model by immunization with a non-toxic multiepitopic protein (rMEPLox). This immunogen contains epitopes from an astacin-like metalloprotease, a hyaluronidase and a sphingomyelinase-D from Loxosceles intermedia and from SMase-I from L. laeta venoms. In vivo protection assays showed that five out of six mice immunized with rMEPLox (after six injections) resisted to 1.4 LD₅₀ of L. laeta venom, whereas only two animals from a control group survived. The present results indicates that this multiepitopic protein can be a promising candidate for anti-loxoscelic antivenom production and experimental vaccination approaches.

Original language	American English
Pages (from-to)	1-5
Number of pages	5
Journal	Toxicon
Volume	215
DOIs	https://doi.org/10.1016/j.toxicon.2022.05.044
State	Indexed - Aug 2022
Externally published	Yes

Bibliographical note

Funding Information:
This study was funded by 021-2019-FONDECYT-PROCIENCIA-BM-Incorporación de Investigadores-Perú, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq) (Process: 406163/2018–9 ) and by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) , Brazil - (Program COFECUB Process: 88881.191812/2018–01 ).

Publisher Copyright:
© 2022 Elsevier Ltd

Keywords

Hyaluronidase
In vivo protection
Loxosceles laeta spider
Metalloprotease
Multiepitopic protein
Sphyngomielinase-D

Access to Document

10.1016/j.toxicon.2022.05.044

Cite this

@article{02b47a741c5f4094ac67eb7aa92feb94,

title = "Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox)",

abstract = "Loxoscelism is a serious public health problem in Peru, with approximately 2500 accidents reported per year. To envision alternatives to cope with this health problem, the neutralizing humoral immune response against the lethal effects of Peruvian spider Loxosceles laeta venom was evaluated in a mouse model by immunization with a non-toxic multiepitopic protein (rMEPLox). This immunogen contains epitopes from an astacin-like metalloprotease, a hyaluronidase and a sphingomyelinase-D from Loxosceles intermedia and from SMase-I from L. laeta venoms. In vivo protection assays showed that five out of six mice immunized with rMEPLox (after six injections) resisted to 1.4 LD50 of L. laeta venom, whereas only two animals from a control group survived. The present results indicates that this multiepitopic protein can be a promising candidate for anti-loxoscelic antivenom production and experimental vaccination approaches.",

keywords = "Hyaluronidase, In vivo protection, Loxosceles laeta spider, Metalloprotease, Multiepitopic protein, Sphyngomielinase-D",

author = "Quispe, {Ruth L.} and Jaramillo, {Michael L.} and Frank Torres-Huaco and Cesar Bonilla and Jacqueline Isasi and Clara Guerra-Duarte and Carlos Ch{\'a}vez-Ol{\'o}rtegui",

note = "Funding Information: This study was funded by 021-2019-FONDECYT-PROCIENCIA-BM-Incorporaci{\'o}n de Investigadores-Per{\'u}, Conselho Nacional de Desenvolvimento Cient{\'i}fico e Tecnol{\'o}gico, Brazil (CNPq) (Process: 406163/2018–9 ) and by Coordena{\c c}{\~a}o de Aperfei{\c c}oamento de Pessoal de N{\'i}vel Superior (CAPES) , Brazil - (Program COFECUB Process: 88881.191812/2018–01 ). Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = aug,

doi = "10.1016/j.toxicon.2022.05.044",

language = "American English",

volume = "215",

pages = "1--5",

journal = "Toxicon",

issn = "0041-0101",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox)

AU - Quispe, Ruth L.

AU - Jaramillo, Michael L.

AU - Torres-Huaco, Frank

AU - Bonilla, Cesar

AU - Isasi, Jacqueline

AU - Guerra-Duarte, Clara

AU - Chávez-Olórtegui, Carlos

N1 - Funding Information: This study was funded by 021-2019-FONDECYT-PROCIENCIA-BM-Incorporación de Investigadores-Perú, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (CNPq) (Process: 406163/2018–9 ) and by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) , Brazil - (Program COFECUB Process: 88881.191812/2018–01 ). Publisher Copyright: © 2022 Elsevier Ltd

PY - 2022/8

Y1 - 2022/8

N2 - Loxoscelism is a serious public health problem in Peru, with approximately 2500 accidents reported per year. To envision alternatives to cope with this health problem, the neutralizing humoral immune response against the lethal effects of Peruvian spider Loxosceles laeta venom was evaluated in a mouse model by immunization with a non-toxic multiepitopic protein (rMEPLox). This immunogen contains epitopes from an astacin-like metalloprotease, a hyaluronidase and a sphingomyelinase-D from Loxosceles intermedia and from SMase-I from L. laeta venoms. In vivo protection assays showed that five out of six mice immunized with rMEPLox (after six injections) resisted to 1.4 LD50 of L. laeta venom, whereas only two animals from a control group survived. The present results indicates that this multiepitopic protein can be a promising candidate for anti-loxoscelic antivenom production and experimental vaccination approaches.

AB - Loxoscelism is a serious public health problem in Peru, with approximately 2500 accidents reported per year. To envision alternatives to cope with this health problem, the neutralizing humoral immune response against the lethal effects of Peruvian spider Loxosceles laeta venom was evaluated in a mouse model by immunization with a non-toxic multiepitopic protein (rMEPLox). This immunogen contains epitopes from an astacin-like metalloprotease, a hyaluronidase and a sphingomyelinase-D from Loxosceles intermedia and from SMase-I from L. laeta venoms. In vivo protection assays showed that five out of six mice immunized with rMEPLox (after six injections) resisted to 1.4 LD50 of L. laeta venom, whereas only two animals from a control group survived. The present results indicates that this multiepitopic protein can be a promising candidate for anti-loxoscelic antivenom production and experimental vaccination approaches.

KW - Hyaluronidase

KW - In vivo protection

KW - Loxosceles laeta spider

KW - Metalloprotease

KW - Multiepitopic protein

KW - Sphyngomielinase-D

UR - http://www.scopus.com/inward/record.url?scp=85131359244&partnerID=8YFLogxK

U2 - 10.1016/j.toxicon.2022.05.044

DO - 10.1016/j.toxicon.2022.05.044

M3 - Original Article

C2 - 35660625

AN - SCOPUS:85131359244

SN - 0041-0101

VL - 215

SP - 1

EP - 5

JO - Toxicon

JF - Toxicon

ER -

Partial in vivo protection against Peruvian spider Loxosceles laeta venom by immunization with a multiepitopic protein (rMEPLox)

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this